Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Income from Continuing Operations (2023 - 2025)

Historic Income from Continuing Operations for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$15.8 million.

  • Compass Therapeutics' Income from Continuing Operations fell 2923.44% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 4154.73%. This contributed to the annual value of -$56.6 million for FY2024, which is 3325.41% down from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Income from Continuing Operations is -$15.8 million, which was down 2923.44% from -$21.1 million recorded in Q2 2025.
  • Compass Therapeutics' Income from Continuing Operations' 5-year high stood at -$7.8 million during Q1 2023, with a 5-year trough of -$21.1 million in Q2 2025.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$13.1 million (2024), whereas its average is -$13.5 million.
  • Per our database at Business Quant, Compass Therapeutics' Income from Continuing Operations tumbled by 1594.25% in 2024 and then crashed by 6110.43% in 2025.
  • Over the past 3 years, Compass Therapeutics' Income from Continuing Operations (Quarter) stood at -$13.4 million in 2023, then decreased by 23.55% to -$16.6 million in 2024, then grew by 4.57% to -$15.8 million in 2025.
  • Its Income from Continuing Operations stands at -$15.8 million for Q3 2025, versus -$21.1 million for Q2 2025 and -$16.6 million for Q1 2025.